Gapping up
In reaction to strong earnings/guidance:
- TNDM +19.6%, PANW +11.4%, BBY +11%, FTR +10.8%, CHK +10.6%, SE +10.5%, OCN +9.9%, MELI +9.6%, GWPH +8.9%, DNR +8.9%, JAZZ +8%, HZNP +7.2%, PUMP +7%, SUPN +6.8%, IMAX +6.5%, INSP +6.4%, WMGI +6.4%, MIDD +6%, OPRX +5.4%, CPB +5.2%, INN +5%, SHOO +4.8%, ODP +4.6%, GTE +4.4%, OAS +4.2%, HEI +4.2%, AXGN +3.4%, PLNT +3.4%, LOW +3.4%, RTRX +3.1%, CPE +3%, IONS +3%, COKE +2.8%, MMSI +2.6%, OUT +2.5%, TOL +2.4%, ARNA +2.3%, VEEV +2.2%, CGBD +2%, MASI +1.8%, PZZA +1.3%, SBGI +1.3%, RIO +1.2%, MED +1.1%, PSA +1%, .
Other news:
- MAXR +9% (ahead of earnings Feb 28)
- LTHM +6.6% (to join S&P SmallCap 600)
- HRTX +3.5% (announces FDA approval for CINVANTI for IV use NDA)
- REI +3.4% (Ring Energy to acquire North Central Basin Assets from Wishbone Energy Partners)
- SRPT +2.7% (exercises option to acquire Myonexus Therapeutics; exercise fee is $165 mln)
- NIO +2.5% (continued strength)
- VSI +2.4% (files 135.8K share common stock offering by selling stockholders)
- QURE +2.1% (presents new preclinical data on AMT-130 in Huntington's disease)
- GE +1.3% (to focus on power, renewable energy, aviation and healthcare segments; from 10-K: Targeting leverage <2.5x and dividend in-line with peers over time)
Analyst comments:
- PM +1.2% (upgraded to Buy from Neutral at UBS)
